You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    AbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Development of user-friendly fluorescence based assays for marine toxins

    SBC: SEATOX RESEARCH INC            Topic: 113

    ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Microfluidic Nitric Oxide Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    PROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Interactive technology for media literacy drug prevention in community groups

    SBC: REAL PREVENTION LLC            Topic: NIDA

    The goals of this Phase II STTR are to evaluate the outcomes of REAL mediaan interactiveselfpacede learning substance use prevention media literacy curriculum and prepare it for marketing to community organizationsincluding our partnerHSubstance use increases in frequency and risk through mid adolescenceyet prevention interventions primarily target early useare time intensiveand are implemented in ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. AutoRegister: A system for enhancing the accuracy of tumor change detection

    SBC: CORTICOMETRICS LLC            Topic: 102

    PROJECT SUMMARY This project proposes to continue the development of AutoRegisterTMan integrated software based system for enhancing the accuracy of tumor change detectionThe intent of the system is to automate the alignment of a patient s brain scan with that of a prior scan such that subsequent offline tumor measurements do not have error introduced solely by differing slice orientationsWhile si ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases

    SBC: Eyedesis Biosciences, LLC            Topic: N

    PROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer

    SBC: Mekanistic Therapeutics, LLC            Topic: NCI

    PROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    Project Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Development Characterization and Commercialization of a Viably Frozen Patient Inclusive Hepatocellular Carcinoma Tumor Bank

    SBC: Woodland Pharmaceuticals LLC            Topic: 103

    Abstract Hepatocellular carcinoma HCC is a disease of growing incidence globally including in the US by per year With the recent success of anti viral therapies the etiology of HCC in the American population is projected to shift from viral HBV HCV hepatitis to primarily fatty liver disease in the near future Currently only one effective systemic therapy has been developed for HCC ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of PAR Pepducins as a Novel Antithrombotic Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Coronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregation and secretion are key components of arterial thrombus formation Despite dual anti platelet therapy for ACS and percutaneous coronary interventions PCI many patients sustain a high incidence u ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government